GAMMA Investing LLC Takes $1.29 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

GAMMA Investing LLC bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,390 shares of the medical research company's stock, valued at approximately $1,288,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Raleigh Capital Management Inc. boosted its holdings in Thermo Fisher Scientific by 49.1% during the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company's stock worth $41,000 after buying an additional 27 shares in the last quarter. Cedar Mountain Advisors LLC boosted its holdings in Thermo Fisher Scientific by 107.0% during the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company's stock worth $47,000 after buying an additional 46 shares in the last quarter. Operose Advisors LLC boosted its holdings in Thermo Fisher Scientific by 250.0% during the third quarter. Operose Advisors LLC now owns 105 shares of the medical research company's stock worth $53,000 after buying an additional 75 shares in the last quarter. Financial Connections Group Inc. purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth about $53,000. Finally, Valley National Advisers Inc. boosted its holdings in Thermo Fisher Scientific by 40.5% during the third quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company's stock worth $56,000 after buying an additional 32 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

TMO has been the topic of a number of research analyst reports. Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an "outperform" rating in a report on Thursday, February 1st. Evercore ISI upped their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an "outperform" rating in a report on Thursday, April 4th. Royal Bank of Canada upped their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an "outperform" rating in a report on Thursday, February 1st. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Finally, Citigroup assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They issued a "neutral" rating and a $620.00 price target on the stock. Five research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $604.69.

Thermo Fisher Scientific Trading Up 4.9 %

TMO stock traded up $26.72 on Tuesday, hitting $575.10. 2,543,876 shares of the company were exchanged, compared to its average volume of 1,562,261. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The business's fifty day moving average is $571.30 and its two-hundred day moving average is $528.18. The stock has a market capitalization of $219.52 billion, a price-to-earnings ratio of 37.19, a price-to-earnings-growth ratio of 2.30 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the prior year, the business posted $5.40 earnings per share. Thermo Fisher Scientific's revenue for the quarter was down 4.9% compared to the same quarter last year. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific's dividend payout ratio is 10.10%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the business's stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the business's stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares of the company's stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock worth $28,513,384 over the last ninety days. 0.32% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.